Previous 10 | Next 10 |
peterschreiber.media/iStock via Getty Images Nevro Corp. ([[NVRO]] +5.4%) continues to trade higher after the company announced the FDA approval of its Senza Spinal Cord Stimulation ((SCS)) system as a treatment of chronic pain linked to Painful Diabetic Neuropathy ((PDN)). Commenting on...
Nevro Corp. (NYSE:NVRO) traded today at a new 52-week high of $152.31. Approximately 235,000 shares have changed hands today, as compared to an average 30-day volume of 13,000 shares. Nevro Corp. share prices have moved between a 52-week high of $152.31 and a 52-week low of $0.02 and are...
Nevro (NVRO) has received FDA approval for its Senza System for the treatment of chronic pain associated with Painful Diabetic Neuropathy ((PDN)).The company will immediately initiate commercial launch activities in the U.S. under its recently launched HFX branding, as HFX for PDN.Internation...
Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN) HFX™ for PDN Now the Only Spinal Cord Stimulation System Approved by FDA to Treat PDN¹ Compan...
Nevro to Report Second Quarter 2021 Financial Results Company to Host Conference Call on Wednesday, August 4, 2021, at 1:30 pm PT / 4:30 pm ET PR Newswire REDWOOD CITY, Calif. , July 7, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical...
Viktoriia Hnatiuk/iStock via Getty Images Hologic upgraded on tuck-in M&A strategy Evercore ISI is upgrading shares of Hologic ([[HOLX]] -0.4%) to outperform with a $78 price target (~15% upside). The firm says that the women's health and diagnostics player is poised for future tuck-in ac...
P_Wei/E+ via Getty Images Cassava Sciences is on recovery as B Riley lifts price target After a loss of ~13.5% yesterday, Cassava Sciences (SAVA) has recovered today rising ~2.6% in the premarket after B Riley Securities raised its price target to $111.00 from $78.00 per share imply...
Nevro Announces SENZA-PDN Clinical Data Presentation at the American Diabetes Association 81st Scientific Sessions Late Breaking Poster Presentation to Include Complete 12-Month Follow-Up Results and 6-Month Crossover Patient Data for SENZA-PDN Randomized Controlled Trial Co...
Nevro Announces SENZA-NSRBP Clinical Data Presentation at the American Society of Interventional Pain Physicians 23rd Annual Meeting Podium Presentation to Include Complete 6-Month Follow-Up Results for SENZA-NSRBP Randomized Controlled Trial Company to Host Investor Briefin...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...